Pulpitis - Irreversible
Conditions
Keywords
pulpal regeneration, pulpitis, pulpotomy
Brief summary
The aim of this study was to clinically and radiographically evaluate the effectiveness of MTA, Biodentine, Platelet Rich Fibrin along with Mineral Trioxide Aggregate and Platelet Rich Fibrin along with Biodentine as pulpotomy medicament in patients with pulpitis.
Detailed description
Sixty systemically healthy patients with irreversible pulpitis were enrolled in the study based on inclusion and exclusion criteria. All the enrolled patients were randomly allocated into 4 groups (15 each) Group I: MTA GROUP: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent. Group II: BIODENTINE GROUP: Vital Pulpotomy will be done using Biodentine as pulp capping agent. Group III: PRF + MTA GROUP: Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent. Group IV: PRF+ BIODENTINE GROUP: Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent Patients were assessed at 1 day,3 months, 6 months and 9 months postoperatively for pain, pulp sensitivity test, swelling or presence of any sinus tract. All the proposed teeth were assessed radiographically at1 day, 3 months, 6 months and 9 months postoperatively.
Interventions
DRUGMineral trioxide aggregate
Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
DRUGBiodentine
Vital Pulpotomy will be done using Biodentine as pulp capping agent
BIOLOGICALPlatelet rich fibrin
10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit. The product obtained after centrifugation consisted of three layers: * Acellular platelet plasma- top most layer * Platelet rich fibrin -middle layer * Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece
Sponsors
Maharishi Markendeswar University (Deemed to be University)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
patient and statistician are masked about the treatment modality.
Intervention model description
Sixty systemically healthy patients with irreversible pulpitis were enrolled in the study based on inclusion and exclusion criteria. All the enrolled patients were randomly allocated into 4 groups (15 each) Group I: MTA GROUP: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent. Group II: BIODENTINE GROUP: Vital Pulpotomy will be done using Biodentine as pulp capping agent. Group III: PRF + MTA GROUP: Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent. Group IV: PRF+ BIODENTINE GROUP: Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
Eligibility
Sex/Gender
ALL
Age
20 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Patients with carious exposed tooth exhibiting clinical and radiographical evidence for pulpitis. * Deep caries extending ≥2/3 of dentin. * Tooth with positive response with cold testing. * Tooth with no mobility. * No signs of pulpal necrosis including sinus tract or swelling. * Patient approval for the treatment and follow up
Exclusion criteria
* Any systemic disease that could influence the outcome. * Non-restorable tooth. * Teeth with periapical widening. * Tooth which cannot be isolated. * Teeth with marginal periodontitis or crestal bone loss. * Indication of post/ post and core restoration marginal periodontitis with attachment loss \>5mm. * Teeth with immature root or calcified canal. * Teeth with internal and external resorption. * No pulp exposure after caries excavation. * Uncontrolled bleeding after access cavity preparation after several minutes N * No bleeding at all at the time of access opening * Pregnant or nursing women. * Individual hypersensitive or allergic to any product used in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cold test | change from baseline to 1day, 3 months, 6 months, 9 months | cold test |
| EPT | change from baseline to 1day, 3 months, 6 months, 9 months | Electric pulp testing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tender on percussion | change from baseline to 1day, 3 months, 6 months, 9 months | present or absent |
| swelling | change from baseline to 1day, 3 months, 6 months, 9 months | present or absent |
Countries
India
Outcome results
None listed